PMID- 10570420
OWN - NLM
STAT- MEDLINE
DCOM- 20000104
LR  - 20190620
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 86
IP  - 10
DP  - 1999 Nov 15
TI  - Mucin core protein expression in extrahepatic bile duct carcinoma is associated
      with metastases to the liver and poor prognosis.
PG  - 1966-75
AB  - BACKGROUND: Curative resection does not guarantee long term survival for the
      patient with extrahepatic bile duct carcinoma because of the possibility of
      metastases to the liver (LM). Expression of mucin core protein-1 (MUC1),
      sialyl-Le(x), and sialosyl-Tn in bile duct carcinoma was determined and compared 
      with LM and prognosis. METHODS: Immunohistochemical expression of MUC1,
      sialyl-Le(x), and sialosyl-Tn in 73 extrahepatic bile duct tumors was analyzed
      using the DF3, FH6, and TKH2 monoclonal antibodies, respectively. Scoring was
      based on the percentage of immunoreactive cells: negative, low expression (</=25%
      immunoreactive cells), and high expression (>25%). RESULTS: High expression of
      MUC1, sialyl-Le(x), and sialosyl-Tn was observed in 68.5%, 34.2%, and 54.8%,
      respectively. of 73 cases. Patients with tumors showing high expression of MUC1
      had a higher rate of LM (48.9%) and a significantly shorter survival period
      (median survival time, 17.8 months) compared with patients with tumors showing
      low (incidence of LM, 9.1%; median survival time, >100 months) or negative
      (incidence of LM, 11.1%; median survival time, 52.9 months) expression of MUC1 (P
      < 0.01). However, the survival period of patients with tumors showing high, low, 
      or negative expression of sialyl-Le(x) or of sialosyl-Tn did not differ
      significantly. High MUC1 expression correlated with LM by logistic regression
      analysis and emerged as an independent prognostic factor in stepwise multivariate
      analysis. CONCLUSIONS: The results of the current study demonstrate that high
      expression of MUC1 correlates with LM and poor outcome in patients with
      extrahepatic bile duct carcinoma.
CI  - Copyright 1999 American Cancer Society.
FAU - Takao, S
AU  - Takao S
AD  - First Department of Surgery, Kagoshima University School of Medicine, Kagoshima, 
      Japan.
FAU - Uchikura, K
AU  - Uchikura K
FAU - Yonezawa, S
AU  - Yonezawa S
FAU - Shinchi, H
AU  - Shinchi H
FAU - Aikou, T
AU  - Aikou T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 0
      (5-acetylneuraminyl-(2-3)-galactosyl-(1-4)-(fucopyranosyl-(1-3))-N-acetylglucosam
      ine)
RN  - 0 (Antigens, Tumor-Associated, Carbohydrate)
RN  - 0 (Glycoproteins)
RN  - 0 (MUC1 tandem repeat peptide)
RN  - 0 (Mucin-1)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Oligosaccharides)
RN  - 0 (Peptide Fragments)
RN  - 0 (sialosyl-Tn antigen)
SB  - AIM
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antigens, Tumor-Associated, Carbohydrate/biosynthesis
MH  - Bile Duct Neoplasms/*metabolism
MH  - Glycoproteins/biosynthesis
MH  - Humans
MH  - Liver Neoplasms/*secondary
MH  - Logistic Models
MH  - Middle Aged
MH  - Mucin-1/*biosynthesis
MH  - Neoplasm Proteins/*biosynthesis
MH  - Oligosaccharides/biosynthesis
MH  - Peptide Fragments/*biosynthesis
MH  - Prognosis
MH  - Retrospective Studies
EDAT- 1999/11/26 00:00
MHDA- 1999/11/26 00:01
CRDT- 1999/11/26 00:00
PHST- 1999/11/26 00:00 [pubmed]
PHST- 1999/11/26 00:01 [medline]
PHST- 1999/11/26 00:00 [entrez]
AID - 10.1002/(SICI)1097-0142(19991115)86:10<1966::AID-CNCR13>3.0.CO;2-M [pii]
AID - 10.1002/(sici)1097-0142(19991115)86:10<1966::aid-cncr13>3.0.co;2-m [doi]
PST - ppublish
SO  - Cancer. 1999 Nov 15;86(10):1966-75. doi:
      10.1002/(sici)1097-0142(19991115)86:10<1966::aid-cncr13>3.0.co;2-m.